Kelly Martin has been named permanent CEO of Novan (NASDAQ: NOVN). The Morrisville, NC-based drug developer appointed Martin interim CEO last June, part of a corporate shakeup in which the company laid off 20 percent of its staff and shifted founding CEO Nathan Stasko to chief scientific officer. Those moves followed the failure of SB204, a topical gel developed to treat acne, in one of two Phase 3 studies in early 2017.
UNDERWRITERS AND PARTNERS